Abstract：
The Toxicology Investigators Consortium (ToxIC) was launched as a prospective multi-center registry of cases who receive medical toxicology consultations. Now, with over 100,000 cases, the Core Registry continues to address many medical toxicology research questions and has served as the foundation for multiple sub-registries, including the North American Snakebite Registry and the Medications for Opioid Use Disorder sub-registry. ToxIC also has evolved a portfolio of non-registry-based projects utilizing medical toxicology physician site principal investigators who enroll patients through emergency departments, irrespective of whether they received a medical toxicology consultation. These studies include the FDA-ACMT COVID-19 ToxIC Pharmacovigilance Project, which identifies adverse drug reactions related to the treatment of COVID-19, the Fentalog Study a toxico-surveillance study of suspected opioid overdose cases, the Drug Overdose Toxico-Surveillance Reporting Program which enrolls either suspected stimulant or opioid overdose cases, and the just being launched Real-World Examination of Naloxone for Drug Overdose Reversal project. Given ToxIC\'s experience in multi-center studies and its well-developed infrastructure, it is well-positioned to provide a nimble response on the part of the medical toxicology community to addressing evolving toxicological threats, drug and chemical toxicosurveillance, and other important medical toxicology priorities.
摘要：
毒理学研究者联盟（ToxIC）是作为接受医学毒理学咨询的病例的前瞻性多中心注册表而启动的。现在,超过10万例，核心注册中心继续解决许多医学毒理学研究问题，并作为多个分注册中心的基础，包括北美蛇咬伤登记处和阿片类药物使用障碍子登记处。ToxIC还开发了一系列非注册项目，利用医疗毒理学医师现场主要调查人员通过急诊科招募患者，不管他们是否接受了医学毒理学咨询。这些研究包括FDA-ACMTCOVID-19有毒物质药物警戒项目，该研究确定了与COVID-19治疗相关的药物不良反应，Fentalog研究是对疑似阿片类药物过量病例的毒性监测研究，药物过量毒性监测报告计划，该计划登记疑似兴奋剂或阿片类药物过量病例，以及刚刚启动的纳洛酮药物过量逆转项目的真实世界检查。鉴于ToxIC在多中心研究方面的经验及其发达的基础设施，它处于有利地位，可以为医学毒理学界提供灵活的应对措施，以应对不断发展的毒理学威胁，药物和化学毒物监测,和其他重要的医学毒理学优先事项。
